drugset / Trial / NCT03943147

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

NCT03943147

Phase 2 Terminated 16 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).

Timeline

Start
2019-07-15
Primary completion
2020-10-29
Completion
2021-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule
Background Mycophenolate Mofetil Small molecule

Indications